iNtRON Biotechnology, Inc.
KOSDAQ
₩2,695.00
+0.75%
Delayed · cached 15 min
Price Chart
Price50-day avg200-day avg
How to read this: the line is the closing price over time. The two dashed lines are moving averages — the average price over the last 50 and 200 trading days — which smooth out daily noise to show the broader trend. Price above its moving averages reflects recent strength; below reflects recent weakness. Use the buttons to change the time range. Prices are end-of-day, not live.
✓Strengths
- Low debt: debt-to-equity of 0.06.
- Current assets comfortably cover current liabilities (current ratio 10.72).
!Watch-points
- Thin interest cover: operating profit covers interest only about -2.6 times.
- Return on equity is on the lower side at -12.8%.
- Return on capital employed is on the lower side at -11.3%.
- The company reported a net loss in the latest period.
- Sales growth has been slow over five years (about -6% a year).
These points are generated automatically from the company’s reported figures to highlight what stands out. They are descriptive observations for educational purposes only — not advice or a recommendation to buy, sell, or hold.
Forensic Checks
Altman Z-ScoreDistress zone
0.8
In Altman’s study, scores in this range were associated with a higher incidence of financial distress.
Computed without the market-value term.
Piotroski F-ScoreWeak
2 / 5
The F-Score adds one point for each of several year-on-year signs of improving profitability, lower leverage and better efficiency. Higher is generally stronger.
Based on 5 of the 9 signals — the rest need data not available for this stock.
These are well-known academic screening models, shown for educational context only. They describe historical financial patterns and are not predictions, advice, or a recommendation to buy, sell, or hold.
Key Ratios
Market Cap₩833억
Current Price₩ 2,695.00
High / Low₩ 7,010.00 / 0.00
Stock P/E-9.52
Book Value₩ 2,210.21
ROCE-11.25%
ROE-12.82%
Debt to Equity0.06
Current Ratio10.72
EPS₩ -283.00
PAT Margin-156.06%
ICR-2.62
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity